Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.